Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04413201
Title AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC
Recruitment Recruiting
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Michael Hopp

lung non-small cell carcinoma


Afatinib + Osimertinib


Age Groups: adult | senior
Covered Countries DEU

No variant requirements are available.